Adrenal lesions in acromegaly: Do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up

Journal of Endocrinological Investigation

Volumn 34, Issue 5, 2011, Pages 353-360

  Occhi, G ^a   Albiger, N M ^a   Rizzati, S ^a   Ferasin, S ^a   Trivellin, G ^a   Mantero, F ^a   Scaroni, Carla ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acromegaly; Adrenal gland neoplasm; Aryl hydrocarbon receptor interacting protein; Body mass index; Insulin resistance

Indexed keywords

GROWTH HORMONE; INSULIN; SOMATOMEDIN C;

ACROMEGALY; ADRENAL TUMOR; ADULT; AGED; ARTICLE; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN GENE; BODY MASS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; FEMALE; FOLLOW UP; GENE MUTATION; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; TUMOR SUPPRESSOR GENE; WAIST HIP RATIO;

EID: 79960274982     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7145     Document Type: Article

References (49)

1. Bertherat J, Mosnier-Pudar H, Bertagna X. Adrenal incidentalomas. Curr Opin Oncol 2001, 14: 58-63. (Pubitemid 34072965)
2. Mantero F, Albiger N. A comprehensive approach to adrenal incidentalomas. Arq Bras Endocrinol & Metab 2004, 48: 583-91.
3. Beuschlein F. Adrenal incidentalomas: presentation and clinical work-up. Horm Res, 2007, 68: 191-94.
4. Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol 2008, 61: 1168-73.
5. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558-73.
6. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly; epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
7. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol 2006, 64: 115-21.
8. Loeper S, Ezzat S. Acromegaly: Re-thinking the cancer risk. Rev Endocr Metab Disord 2008, 9: 41-58.
9. Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 161-7. (Pubitemid 41097984)
10. Colao AM, Pivonello R, Auriemma RS, et al. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab 2007, 92: 3854-60. (Pubitemid 47607633)
11. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis. World J Gastroenterol 2008, 14: 3484-9.
12. Scaroni C, Selice R, Benedini S, et al. Adrenal morpho-functional alterations in patients with acromegaly. J Endocrinol Invest 2008, 31: 602-6.
13. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312: 1228-30.
14. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl Hydrocarbon Receptor Interacting Protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92: 1891-6. (Pubitemid 46997206)
15. Georgitsi M, Karhu A, Winqvist R, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007, 96: 352-6.
16. Raitila A, Georgitsi M, Karhu A, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 2007, 14: 901-6. (Pubitemid 350074077)
17. Raitila A, Georgitsi M, Bonora E, et al. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest 2009, 32: 426-9.
18. Cazabat L, Libè, R, Perlemoine K, et al. Germline inactivating mutations of the Aryl Hydrocarbon Receptor-Interacting Protein gene in a large cohort of sporadic acromegaly: mutations are found in a Subset of young patients with macroadenomas. Eur J Endocrinol 2007, 157: 1-8. (Pubitemid 47162559)
19. Leontiou CA, Gueorguiev M, Van Der Spuy J, et al. The role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93: 2390-1.
20. Toledo RA, Mendonca BB, Fragoso MC, et a. Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo) 2010, 65: 407-15.
21. Cordero RA, Barkan AL. Current diagnosis of acromegaly. Rev Endocr Metab Disord 2008, 9: 13-9.
22. Grottoli S, Razzore P, Gaia D, et al. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 2003, 26: 123-27. (Pubitemid 36503058)
23. Friedrich N, Alte D, Volzke H, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res 2008, 18: 228-37. (Pubitemid 351479927)
24. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509-17.
25. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract ResClin Endocrinol Metab 2009, 232: 245-59.
26. Terzolo M, Bovio S, Pia A, et al. Subclinical Cushing's syndrome. Arq Bras Endocrinol Metabol 2007, 51: 1272-9.
27. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli G. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009, 23: 233-43.
28. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care 2004, 27: 1487-95.
29. Bravata DM, Wellsa CK, Concato J, Keman WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. J Clin Epidemiol 2004, 57: 1214-7. (Pubitemid 39573031)
30. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005, 54: 1914-25. (Pubitemid 40911252)
31. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294, E15-26.
32. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25: 1751-62. (Pubitemid 47356612)
33. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138: 424-9. (Pubitemid 36262654)
34. Occhi G, Jaffrain-Rea ML, Trivellin G, et al. TThe R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect? J Endocrinol Invest. 2010, 33: 800-5.
35. Occhi G, Trivellin G, Ceccato F, et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol 2010, 163: 369-76.
36. Mantero F, Terzolo M, Arnaldi, G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85: 637-44. (Pubitemid 32273647)
37. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and bio-chemical features. J Clin Endocrinol Metab 2000, 85: 1440-8. (Pubitemid 32289484)
38. Terzolo M, Pia A, Alì A, et al. Adrenal incidentalomas: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002, 87: 998-1003.
39. Ryu S, Sung KC, Chang Y, Lee WJ, Rhee EJ. Spectrum of insulin sensitivity in the Korean population. Metabolism 2005, 54: 1644-51. (Pubitemid 41728158)
40. Rossi GP, Sticchi D, Giuliani L, et al. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J MoI Med 2006, 17: 975-80.
41. Menendez JA, Vazquez-Martin A, Ortega FJ, Fernandez-Real JM. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009, 55: 425-38.
42. Ermetici F, Malavazos AE, Corbetta S., et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 2007, 56: 686-92. (Pubitemid 46574732)
43. De Ferranti S, Mozaffarian D. The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences. Clin Chem 2008, 54: 945-55.
44. Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 2008, 159: 773-9.
45. Katznelson L. Alterations in body composition in acromegaly. Pituitary 2009, 12: 136-42.
46. Barzon L, Sonino N, FaIIo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273-85. (Pubitemid 37304697)
47. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and Scintigraphic Correlates. J Clin Endocrinol Metab 1998, 83. 55-62. (Pubitemid 28498310)
48. Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007, 8: 343-48.
49. Soon PSH, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13: 548-61. (Pubitemid 351872872)